Mitiglinide-Calcium-KAD-1229-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEMitiglinide CalciumCat. No.: HY-17398CAS No.: 145525-41-3Synonyms: KAD-1229; S21403分式: CHNOCa.分量: 334.44作靶點(diǎn): Potassium Channel作通路: Membrane Transporter/Ion Channel儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1

2、month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 5 mg/mL (14.95 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.9901 mL 14.9504 mL 29.9007 mL5 mM 0.5980 mL 2.9901 mL 5.9801 mL10 mM 0.2990 mL 1.4950 mL 2.9901 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑

3、(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 0.5 mg/mL (1.50 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 0.5 mg/mL (1.50 mM); Clear solution3. 請(qǐng)依序添加每種溶劑： 10% DMSO

4、 90% corn oil1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 0.5 mg/mL (1.50 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Mitiglinide Calcium (KAD-1229; S21403)是KATP通道拮抗劑，具有抗2型糖尿病活性。REFERENCES1. Kiyoshi Ichikawa, Tokuhisa Yamato, Kazuma Ojima, et al. Effect Of Kad-1229, A Novel Hypoglycaem

5、ic Agent, On Plasma GlucoseLevels After Meal Load In Type 2 Diabetic Rats. Clinical and Experimental Pharmacology and Physiology. 2002, 29 (5-6): 423-4272. Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channelsand insulin

6、secretion: comparison with the sulfonylureas and nateglinide.European Journal of Pharmacology.2001, 431(1):119-125.3. Kiyoshi Ichikawa, Kazuyasu Maruyama, Makoto Murakami, et al. Absence of exacerbation of myocardial stunning in anesthetized dogstreated with KAD-1229, a novel hypoglycemic agent. Eur

7、opean Journal of Pharmacology.2001, 3(23): 331-3384. Ohnota H, Kitamura T, Kinukawa M, et al. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandialhyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Japanese Journal

8、ofPharmacology.1996, 71(4):315-323.5. Hideo Mogamia, Hiroshi Shibataa, Romi Nobusawaa, et al. Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compoundKAD-1229 in a pancreatic -cell line, MIN 6 cell. European Journal of Pharmacology: Molecular Pharmacology. 1994, 269(3): 293-298McePdfHeightCaution: Product has not been fully validated for medical applications